
|Articles|December 1, 2004
Continue to treat LUTS, ED as two separate entities
As we continue to debate and search for a common treatment for these two diseases, physicians should continue to treat these as two different entities as we have in the past.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
BOND-003 Cohort C: Efficacy Results
4
Individualizing androgen pathway therapy in mCSPC
5








